Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation

Yo Ichi Yamashita, Mitsuo Shimada, Ryosuke Minagawa, Eiji Tsujita, Norifumi Harimoto, Shinji Tanaka, Ken Shirabe, Jun Ichi Miyazaki, Yoshihiko Maehara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We developed a new potent nonviral gene transfer method into mouse muscles in vivo named "electrosonoporation." We tried in this report to treat murine orthotopic hepatocellular carcinoma (HCC) by muscle-targeted mouse interleukin-12 (mIL-12) gene transfer using in vivo electrosonoporation. I.m. administration of the mIL-12 gene with electrosonoporation elevated serum IL-12 and IFN-γ and significantly prolonged the survival periods with both growth inhibition of orthotopic HCC and inhibition of spontaneous lung metastasis. The IL-12 gene therapy reduced the number of microvessels and induced more Mac-1-positive cells into HCC. These results show that muscle-targeted mIL-12 gene therapy for orthotopic HCC using in vivo electrosonoporation is very efficient and is thus promising for further clinical trial.

Original languageEnglish
Pages (from-to)1177-1182
Number of pages6
JournalMolecular Cancer Therapeutics
Volume3
Issue number9
Publication statusPublished - Sep 1 2004

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yamashita, Y. I., Shimada, M., Minagawa, R., Tsujita, E., Harimoto, N., Tanaka, S., ... Maehara, Y. (2004). Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics, 3(9), 1177-1182.